Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML

Mikko Purhonen, Mikael Tatun, Kevin Hung, Oda Tafjord, Shady Adnan-Awad, Perttu Koskenvesa, Sanna Siitonen, Kimmo Porkka, Satu Mustjoki, Signe Danielsson, Henrik Hjorth-Hansen, Ulla Olsson-Strömberg, Takashi Kumagai, Shinya Kimura, David M Ross, Oscar E. Brück

Blood (2024) 144 (Supplement 1): 1780.

https://doi.org/10.1182/blood-2024-207253

Published: 2024

Journal Articles

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

Blood (2021) 138 (Supplement 1): 3601.

https://doi.org/10.1182/blood-2021-149483

Published: 2021

Journal Articles

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

Blood (2021) 138 (Supplement 1): 1477.

https://doi.org/10.1182/blood-2021-145483

Published: 2021

Journal Articles

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD PhD, Kaichi Nishiwaki, MD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, MD PhD, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof., Junichi Sakamoto,, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof.

Blood (2019) 134 (Supplement_1): 4154.

https://doi.org/10.1182/blood-2019-130504

Published: 2019

Journal Articles

Efficacy and Safety of Once-Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CBD) Regimen As Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma. -a Phase 2 Multicenter Trial-

Blood (2018) 132 (Supplement 1): 2160.

https://doi.org/10.1182/blood-2018-99-113788

Published: 2018

Journal Articles

Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

Chikashi Yoshida, MD PhD, Noriyoshi Iriyama, MDPhD, Yuho Najima, Shin Fujisawa, MD PhD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD, PhD, Shinichiro Okamoto, MD PhD, Kimihiro Kawakami, MDPhD, Naoki Takezako, MD PhD, Takashi Kumagai, MD PhD, Kazuma Ohyashiki, MD PhD, Jun Taguchi, MD PhD, Shingo Yano, MD PhD, Tadahiko Igarashi, MD, Yasuji Kouzai, MD PhD, Satoshi Morita, PhD Prof, Junichi Sakamoto, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof

Blood (2016) 128 (22): 1916.

https://doi.org/10.1182/blood.V128.22.1916.1916

Published: 2016

Journal Articles

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD, Kaichi Nishiwaki, MD PhD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof, Junichi Sakamoto, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof

Blood (2016) 128 (22): 791.

https://doi.org/10.1182/blood.V128.22.791.791

Published: 2016

Journal Articles

The Incidence of Pleural Effusion on Dasatinib Treatment Is Associated with CD56 Positive Cell Values One Month after Commencing Dasatinib and Achievement of an Early Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia Patients: Results of a D-First Study

Noriyoshi Iriyama, Shin Fujisawa, MD, Maki Hagihara, MDPhD, Chikashi Yoshida, MD PhD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD PhD, Shinichiro Okamoto, MD PhD, Kawakami Kimihiro, Naoki Takezako, MD PhD, Takashi Kumagai, MD PhD, Koiti Inokuchi, MD PhD, Kazuma Ohyashiki, Jun Taguchi, MD PhD, Shingo Yano, Tadahiko Igarashi, MD PhD, Yasuji Kouzai, MD PhD, Satoshi Morita, PhD, Junichi Sakamoto, MDPhD, Hisashi Sakamaki, MDPhD

Blood (2014) 124 (21): 3142.

https://doi.org/10.1182/blood.V124.21.3142.3142

Published: 2014

Journal Articles

A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study

Maki Hagihara, MDPhD, Noriyoshi Iriyama, MDPhD, Chikashi Yoshida, MD PhD, Shin Fujisawa, MD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD PhD, Naoki Takezako, MD PhD, Kimihiro Kawakami, MD PhD, Shinichiro Okamoto, MD PhD, Koiti Inokuchi, MD PhD, Kazuma Ohyashiki, Takashi Kumagai, MD PhD, Jun Taguchi, MD PhD, Shingo Yano, Tadahiko Igarashi, MD PhD, Yasuji Kouzai, MD PhD, Junichi Sakamoto, MDPhD, Satoshi Morita, PhD, Hisashi Sakamaki, MDPhD

Blood (2014) 124 (21): 1795.

https://doi.org/10.1182/blood.V124.21.1795.1795

Published: 2014

Journal Articles

Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

Blood (2013) 122 (21): 3998.

https://doi.org/10.1182/blood.V122.21.3998.3998

Published: 2013

Journal Articles

Relative Increase of Lymphocytes As Early As 1 Month After Initiation of Dasatinib Is a Reliable Predictor for Achieving Complete Molecular Response At 12 Months in Chronic Phase CML Patients Treated with Dasatinib

Eri Matsuki, MD, PhD, Takashi Kumagai, MD, Koiti Inokuchi, MD, PhD, Kazuteru Ohashi, M.D., Atsushi Shinagawa, MD, PhD, Jin Takeuchi, MD, PhD, Chikashi Yoshida, MD, PhD, Shinichiro Okamoto, MD, PhD, Hisashi Wakita, MD, Yasuji Kozai, MD, Yukari Shirasugi, MD, Shin Fujisawa, MD, Osamu Iwase, MD, Shingo Yano, MD, Kaichi Nishiwaki, MD, Koji Oba, MD, Junichi Sakamoto, MD, Hisashi Sakamaki, MD

Blood (2012) 120 (21): 691.

https://doi.org/10.1182/blood.V120.21.691.691

Published: 2012

Journal Articles

Dasatinib Induces a Higher Molecular Response in Japanese Patients with Chronic Myeloid Leukemia After Imatinib Failure Than in Western Populations: Kanto CML Study

Yoshihiro Hatta, MD, PhD, Koiti Inokuchi, MD, PhD, Takashi Kumagai, MD, Kazuteru Ohashi, MD, Atsushi Shinagawa, MD, Jin Takeuchi, MD, Shinichiro Okamoto, MD, PhD, Hisashi Wakita, MD, Yasuji Kouzai, MD, Yukari Shirasugi, MD, Chikashi Yoshida, MD, Koji Oba, MD, Junichi Sakamoto, MD, Hisashi Sakamaki, MD

Blood (2011) 118 (21): 4448.

https://doi.org/10.1182/blood.V118.21.4448.4448

Published: 2011

Journal Articles

Scutellaria Baicalensis, a Herbal Medicine: Antitumor Activity Against Acute Lymphocytic Leukemia, Lymphoma and Myeloma in Vitro.

Takashi Kumagai, Claudia Muller, Julian C. Desmond, Yasufumi Imai, David Heber, H. Phillip Koeffler

Blood (2004) 104 (11): 4491.

https://doi.org/10.1182/blood.V104.11.4491.4491

Published: 2004

Journal Articles

Anticancer Activity and Induction of Multinucleation in Hematologic Cell Lines Mediated by Ganoderma Lucidum .

Claudia I. Muller, M.D., Takashi Kumagai, M.D., James O’Kelly, Ph.D., Navindra Seeram, Ph.D., David Heber, M.D., Ph.D., H. Phillip Koeffler, M.D.

Blood (2004) 104 (11): 4499.

https://doi.org/10.1182/blood.V104.11.4499.4499

Published: 2004

NARROW

Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Efficacy and Safety of Once-Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CBD) Regimen As Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma. -a Phase 2 Multicenter Trial-

Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

The Incidence of Pleural Effusion on Dasatinib Treatment Is Associated with CD56 Positive Cell Values One Month after Commencing Dasatinib and Achievement of an Early Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia Patients: Results of a D-First Study

A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study

Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

Relative Increase of Lymphocytes As Early As 1 Month After Initiation of Dasatinib Is a Reliable Predictor for Achieving Complete Molecular Response At 12 Months in Chronic Phase CML Patients Treated with Dasatinib

Dasatinib Induces a Higher Molecular Response in Japanese Patients with Chronic Myeloid Leukemia After Imatinib Failure Than in Western Populations: Kanto CML Study

Scutellaria Baicalensis, a Herbal Medicine: Antitumor Activity Against Acute Lymphocytic Leukemia, Lymphoma and Myeloma in Vitro.

Anticancer Activity and Induction of Multinucleation in Hematologic Cell Lines Mediated by Ganoderma Lucidum .

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only